
Overview
Biotechnology firm's fiscal Q1 revenue rose, beating analyst expectations
Net loss for fiscal Q1 narrowed compared to the previous year
Outlook
Enanta anticipates cash resources to fund operations into fiscal 2029
Result Drivers
ROYALTY REVENUE - Revenue increase attributed to higher sales of AbbVie's MAVYRET/MAVIRET, boosting royalty income
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue | Beat | $18.62 mln | $16.14 mln (4 Analysts) |
Q1 EPS |
| -$0.42 |
|
Q1 Net Income |
| -$11.94 mln |
|
Q1 Operating Expenses |
| $29.87 mln |
|
Q1 Operating Income |
| -$11.25 mln |
|
Q1 Pretax Profit |
| -$11.91 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Enanta Pharmaceuticals Inc is $20.00, about 48% above its February 6 closing price of $13.51
Press Release: ID:nBw7WR173a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.